| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 09/16/2010 | US20100234347 Substituted Pteridines substituted with a Four-Membered Heterocycle |
| 09/16/2010 | US20100234346 Novel pyrimidine derivatives |
| 09/16/2010 | US20100234345 Novel compounds as cannabinoid receptor ligands |
| 09/16/2010 | US20100234344 8-oxy-quinoline derivatives as bradykinin b2 receptor modulators |
| 09/16/2010 | US20100234334 Nitric oxide releasing steroids |
| 09/16/2010 | US20100234327 Novel Triazene Compounds For The Treatment Of Cancer |
| 09/16/2010 | US20100234325 4-Peroxycyclophosphamide use thereof |
| 09/16/2010 | US20100234324 Quinazolinamide derivatives |
| 09/16/2010 | US20100234314 Idarubicin for the treatment of lymphoma in a dog |
| 09/16/2010 | US20100234310 Estrogenic compounds and their methods of use |
| 09/16/2010 | US20100234306 Use of a peptide as a therapeutic agent |
| 09/16/2010 | US20100234305 Polymeric delivery formulations of leuprolide with improved efficacy |
| 09/16/2010 | US20100234303 Agents, methods and uses |
| 09/16/2010 | US20100234300 A purified pro-cytolytic peptide; used to treat localized and metastatic prostate cancer; administered intratumorally and/or intraprostatically |
| 09/16/2010 | US20100234298 Matrix protein compositions for induction of apoptosis |
| 09/16/2010 | US20100234292 Methods of assessing a propensity of clinical outcome for a female mammal suffering from breast cancer |
| 09/16/2010 | US20100234289 Integrin binding rgd-lipopeptides with gene transfer activities |
| 09/16/2010 | US20100234283 Immunogenic epitopes, peptidomimetics, and anti-peptide antibodies, and methods of their use |
| 09/16/2010 | US20100234278 Prophylactic and/or therapeutic agents for peripheral neuropathy |
| 09/16/2010 | US20100233810 In vivo production of small interfering rnas that mediate gene silencing |
| 09/16/2010 | US20100233785 Novel methods and interferon deficient substrates for the propagation of viruses |
| 09/16/2010 | US20100233735 Pharmaceuticals and methods for treating hypoxia and screening methods therefor |
| 09/16/2010 | US20100233722 Methods for determining the biological effect and/or activity of r pharmaceutical compositions based on their effect on the methylation status of the DNA |
| 09/16/2010 | US20100233690 Use of genes identified to be involved in tumor development for the development of anti-cancer drugs and diagnosis of cancer |
| 09/16/2010 | US20100233294 Use of tellurium compounds for inhibition of interleukin-converting enzyme |
| 09/16/2010 | US20100233293 Phosphaplatins and their use in the treatment of cancers resistant to cisplatin and carboplatin |
| 09/16/2010 | US20100233279 Compositions And Methods Comprising Analogues Of Radicicol A |
| 09/16/2010 | US20100233270 Delivery of Oligonucleotide-Functionalized Nanoparticles |
| 09/16/2010 | US20100233226 Drug-eluting nanowire array |
| 09/16/2010 | US20100233212 Methods and compositions using listeria for enhancing immunogenicity by prime boost |
| 09/16/2010 | US20100233207 C-glycolipids with enhanced th-1 profile |
| 09/16/2010 | US20100233187 Gene products differentially expressed in cancerous cells |
| 09/16/2010 | US20100233178 Use of antibodies for the vaccination against cancer |
| 09/16/2010 | US20100233173 Multispecific epitope binding proteins and uses thereof |
| 09/16/2010 | US20100233172 Methods of inhibiting quiescent tumor proliferation |
| 09/16/2010 | US20100233171 Differential Drug Sensitivity |
| 09/16/2010 | US20100233170 Fully human antibodies against N-Cadherin |
| 09/16/2010 | US20100233169 Methods for treating obesity using fibroblast growth factor-Like polypeptides |
| 09/16/2010 | US20100233167 Chain reaction creating oligomers from repeat units of binding molecules |
| 09/16/2010 | US20100233166 Novel ido inhibitors and methods of use |
| 09/16/2010 | US20100233165 Internalizing human monoclonal antibodies targeting prostate cancer cells in situ |
| 09/16/2010 | US20100233164 Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents for the treatment of hematopoietic malignancies |
| 09/16/2010 | US20100233161 Novel multifunctional compounds for pharmaceutical purposes |
| 09/16/2010 | US20100233160 Monoclonal Anti-Annexin A3 Antibodies for the Detection of Prostate Carcinoma |
| 09/16/2010 | US20100233154 Targeted binding agents directed to heparanase and uses thereof 463 |
| 09/16/2010 | US20100233153 Novel gene disruptions, compositions and the methods relating thereto |
| 09/16/2010 | US20100233152 Use of HMGB proteins and nucleic acids that code therefor |
| 09/16/2010 | US20100233143 Parthenogenic Activation of Human Oocytes for the Production of Human Embryonic Stem Cells |
| 09/16/2010 | US20100233127 Targeted vectors for cancer immunotherapy |
| 09/16/2010 | US20100233126 Polypeptide |
| 09/16/2010 | US20100233117 Adjuvant combination formulations |
| 09/16/2010 | US20100233093 Magnetic resonance imaging contrast agent with paramagnetic-inositol phosphates complexes |
| 09/16/2010 | US20100233090 Targeting vector-phospholipid conjugates |
| 09/16/2010 | US20100233089 Imaging of genetic material with magnetic resonance |
| 09/16/2010 | US20100233087 Cyp1b1 nucleic acids and methods of use |
| 09/16/2010 | US20100233083 Microparticles comprising a crosslinked polymer |
| 09/16/2010 | US20100233081 Methods for administration of radiotherapeutic agents |
| 09/16/2010 | US20100233080 Antigen Binding Molecules that Bind EGFR, Vectors Encoding Same, and Uses Thereof |
| 09/16/2010 | US20100233079 Dual Variable Domain Immunoglobulins and Uses Thereof |
| 09/16/2010 | US20100233078 Microorganisms for imaging and/or treatment of tumors |
| 09/16/2010 | CA2755394A1 Methods and compositions for cell-proliferation-related disorders |
| 09/16/2010 | CA2755191A1 Kinase protein binding inhibitors |
| 09/16/2010 | CA2755157A1 10-amino-1,2,3,4-tetrahydropyrido[2,1-a]isoindol-6(10bh)-one derivatives, method for preparing same, and therapeutic uses thereof |
| 09/16/2010 | CA2755121A1 Combination therapy with thiocolchicine derivatives |
| 09/16/2010 | CA2755120A1 7-cycloalkylaminoquinolones as gsk-3 inhibitors |
| 09/16/2010 | CA2755117A1 Substituted fused pyrimidine compounds |
| 09/16/2010 | CA2755045A1 Pyrrolo [2, 3-b] pyridine derivatives for the inhibition of raf kinases |
| 09/16/2010 | CA2754913A1 Pharmaceutical combinations comprising rdea119/bay 869766 for the treatment of specific cancers |
| 09/16/2010 | CA2754909A1 Combination of an indazolylaminopyrrolotriazine and taxane for cancer treatment |
| 09/16/2010 | CA2754891A1 Treatment of pancreatic cancer |
| 09/16/2010 | CA2754846A1 Prostate-specific antigen cleavable prodrugs |
| 09/16/2010 | CA2754808A1 Prodrug forms of kinase inhibitors and their use in therapy |
| 09/16/2010 | CA2754785A1 Addition salts of tromethamine with azabiphenylaminobenzoic acid derivatives as dhodh inhibitors |
| 09/16/2010 | CA2754764A1 Antigen presenting cell targeted cancer vaccines |
| 09/16/2010 | CA2754748A1 Estrogenic compounds and their methods of use |
| 09/16/2010 | CA2754613A1 Piperazine compound capable of inhibiting prostaglandin d synthase |
| 09/16/2010 | CA2754603A1 Non-integrating retroviral vector vaccines |
| 09/16/2010 | CA2753285A1 Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents for the treatment of hematopoietic malignancies |
| 09/16/2010 | CA2753135A1 Pyrazolo[1,5-.alpha.]-1,3,5-triazine derivatives, preparation thereof, and therapeutic use thereof |
| 09/16/2010 | CA2748963A1 Tetrahydronaphthalen-2-ol derivatives |
| 09/15/2010 | EP2228654A2 Diagnosis and prevention of cancer cell invasion |
| 09/15/2010 | EP2228448A1 MU-1 member of the cytokine receptor family |
| 09/15/2010 | EP2228435A1 Method for amplification of hematopoietic stem cell using heterocyclic compound |
| 09/15/2010 | EP2228434A1 Amplification method for hematopoietic stem cells with heterocyclic compound |
| 09/15/2010 | EP2228392A1 Monoclonal antibody capable of binding to anexelekto, and use thereof |
| 09/15/2010 | EP2228389A2 Antibodies against vascular endothelial growth factor 2 |
| 09/15/2010 | EP2228380A1 Novel triterpene derivatives |
| 09/15/2010 | EP2228364A1 Acylsulfonamides as inhibitors of steroid sulfatase |
| 09/15/2010 | EP2228074A1 A tumor targeting protein conjugate and a method for preparing the same |
| 09/15/2010 | EP2228072A1 Cancer vaccine composition |
| 09/15/2010 | EP2227489A2 Method for the detection of dead and dying cells |
| 09/15/2010 | EP2227474A1 Azo and diaza derivatives and uses thereof in phototherapy |
| 09/15/2010 | EP2227473A2 Polymorphs of a c-met/hgfr inhibitor |
| 09/15/2010 | EP2227470A1 Naphthalene diimide compounds interacting with g-quadruplex regions in dna |
| 09/15/2010 | EP2227469A1 Mapk/erk kinase inhibitors |
| 09/15/2010 | EP2227460A1 Therapeutic oxy-phenyl-aryl compounds and their use |
| 09/15/2010 | EP2227456A2 Hedgehog pathway antagonists and therapeutic applications thereof |
| 09/15/2010 | EP2227244A1 Cgrp as a therapeutic agent |
| 09/15/2010 | EP2227236A2 Methods and compositions for reducing activity of the atrial natriuretic peptide receptor and for treatment of diseases |
| 09/15/2010 | EP2227233A2 Ido inhibitors |